{
    "clinical_study": {
        "@rank": "82373", 
        "arm_group": {
            "arm_group_label": "Patients with POAG or OHT", 
            "description": "Patients with POAG or OHT treated with GANFORT\u00ae UD (fixed combination bimatoprost and timolol) administered in accordance with physician standard practice for up to 12 weeks."
        }, 
        "brief_summary": {
            "textblock": "The study will evaluate patients diagnosed with POAG or OHT who are switched to GANFORT\u00ae UD\n      (unit dose of fixed combination bimatoprost and timolol) therapy for medical reasons in\n      accordance with physician standard clinical practice. All treatment decisions lie with the\n      physician."
        }, 
        "brief_title": "A Study of GANFORT\u00ae UD in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) in a Medical Setting", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Glaucoma, Primary Open Angle", 
            "Ocular Hypertension"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Glaucoma", 
                "Glaucoma, Open-Angle", 
                "Hypertension", 
                "Ocular Hypertension"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosed with primary open-angle glaucoma or ocular hypertension\n\n          -  Previously prescribed intraocular pressure (IOP)-lowering medication with\n             insufficient IOP control and is now being switched to GANFORT\u00ae UD for medical reasons\n\n        Exclusion Criteria:\n\n          -  None"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with primary open-angle glaucoma or ocular hypertension"
            }
        }, 
        "enrollment": {
            "#text": "2000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01999348", 
            "org_study_id": "MAF/AGN/OPH/GLA/039"
        }, 
        "intervention": {
            "arm_group_label": "Patients with POAG or OHT", 
            "description": "Patients with POAG or OHT treated with GANFORT\u00ae UD (fixed combination bimatoprost and timolol) administered in accordance with physician standard practice for up to 12 weeks.", 
            "intervention_name": "Fixed Combination Bimatoprost and Timolol", 
            "intervention_type": "Drug", 
            "other_name": "GANFORT\u00ae UD"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Timolol", 
                "Bimatoprost"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 23, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Wiesloch", 
                    "country": "Germany"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_groups": "1", 
        "overall_contact": {
            "email": "clinicaltrials@allergan.com", 
            "last_name": "Allergan Inc."
        }, 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Germany: Ethics Commission", 
                "Germany: Federal Institute for Drugs and Medical Devices"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from Baseline in Intraocular Pressure (IOP) in the Study Eye", 
            "safety_issue": "No", 
            "time_frame": "Baseline, 12 Weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01999348"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Physician Assessment of IOP-Lowering Effect in the Study Eye on a 3-Point Scale", 
                "safety_issue": "No", 
                "time_frame": "12 Weeks"
            }, 
            {
                "measure": "Patient Assessment of Tolerability on a 4-Point Scale", 
                "safety_issue": "No", 
                "time_frame": "12 Weeks"
            }, 
            {
                "measure": "Physician Assessment of Tolerability on a 4-Point Scale", 
                "safety_issue": "No", 
                "time_frame": "12 Weeks"
            }, 
            {
                "measure": "Percentage of Patients who Discontinue Treatment", 
                "safety_issue": "No", 
                "time_frame": "12 Weeks"
            }, 
            {
                "measure": "Percentage of Patients Prescribed by the Physician to Continue Treatment", 
                "safety_issue": "No", 
                "time_frame": "12 Weeks"
            }, 
            {
                "measure": "Physician Assessment of Patient Compliance Compared to Previous Treatment on a 3-Point Scale", 
                "safety_issue": "No", 
                "time_frame": "12 Weeks"
            }
        ], 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}